Connecticut is currently home to 1246 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of RP-6306 Alone or in Combination with RP-3500 or Debio 0123 in Patients with Advanced Solid Tumors
NCT04855656
Recruiting
The primary purpose of this study is to assess the safety and tolerability of RP-6306 alone and in combination with RP-3500 or in combination with Debio 0123 in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
01/17/2025
Locations: Participating Site # 1012, New Haven, Connecticut
Conditions: Advanced Solid Tumor
Register for Updates
The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults
NCT06027554
Recruiting
The goal of this clinical trial is to test the effects of MitoQ supplementation in older adults and frail older adults with physical dysfunction and/or cognitive dysfunction. The main question\[s\] it aims to answer are: * To compare vascular function, oxidative stress levels, and physical and cognitive function among older adults and frail older adults with physical and cognitive dysfunction * To determine whether MitoQ supplementation has the potential to improve vascular function in central... Read More
Gender:
ALL
Ages:
Between 65 years and 80 years
Trial Updated:
01/16/2025
Locations: UConn Health, Farmington, Connecticut
Conditions: Frailty, Mild Cognitive Impairment, Aging
Register for Updates
HIV and Alcohol Research Center Focused on Polypharmacy (HARP) Pilot 2 (2nd HARP Pilot Intervention)
NCT06513819
Recruiting
The focus of this pilot will be on falls and neurocognitive symptoms, and the impact of alcohol, cannabis use, and medications on these outcomes. The rationale is that alcohol use at any level may interact with neurocognitively active medications, alcohol, and cannabis use leading to falls and impaired cognition.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
01/15/2025
Locations: VA Connecticut Healthcare System, West Haven, Connecticut
Conditions: Hiv, Alcohol Drinking, Fall, Cannabis Use
Register for Updates
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
NCT05183035
Recruiting
A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin \[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse who are unable to receive additional anthracyclines, or in 2nd relapse.
Gender:
ALL
Ages:
Between 29 days and 21 years
Trial Updated:
01/14/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Acute Myeloid Leukemia
Register for Updates
FSL2 Post Approval Study for Pediatric and Young Adults Patients
NCT04959552
Recruiting
This is a prospective, multi-center, non-randomized, single-arm study intended to characterize the safety of the FreeStyle Libre 2 Flash Glucose Monitoring System when used to manage diabetes in pediatric and young adult patient populations.
Gender:
ALL
Ages:
Between 4 years and 30 years
Trial Updated:
01/14/2025
Locations: Yale Pediatric Endocrinology Clinic, New Haven, Connecticut
Conditions: Diabete Mellitus
Register for Updates
Von Willebrand Factor in Pregnancy (VIP) Study
NCT04146376
Recruiting
In pregnant women with von Willebrand disease (VWD) who by the third trimester do not have von Willebrand factor (VWF) or factor VIII (FVIII) levels greater than 50-100%, specific guidance is lacking for delivery planning in terms of how high of a VWF level should be achieved to reduce bleeding. This is a prospective, open-label, cohort study in women with VWD using Wilate VWF replacement therapy to maintain trough or minimum VWF levels of 100-150% for delivery and the immediate postpartum peri... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/14/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Von Willebrand Diseases
Register for Updates
Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients
NCT04217551
Recruiting
A multicenter, randomized, adaptive allocation clinical trial to determine if increasing durations of induced hypothermia are associated with an increasing rate of good neurological outcomes and to identify the optimal duration of induced hypothermia for neuroprotection in comatose survivors of cardiac arrest.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/13/2025
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Cardiac Arrest, Out-Of-Hospital, Hypothermia, Induced, Hypoxia-Ischemia, Brain
Register for Updates
Reversibility of Brain Glucose Transport in Type 2 Diabetes Mellitus (T2DM)
NCT05776563
Recruiting
The goal of this clinical trial is to learn about the effects of high blood glucose levels in the brain and assess if the changes seen in individuals with poorly control T2DM can be reversed with good glucose control. The main question\[s\] it aims to answer are: * To determine, whether abnormalities in brain glucose transport seen in individuals with uncontrolled diabetes, can be improved with better glucose control. * Assess which factors, (duration of diabetes mellitus (DM) and glycemic con... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
01/10/2025
Locations: Yale New Haven Hospital (YNHH) Research Unit (HRU), New Haven, Connecticut
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Mechanisms of Diuretic Resistance in Heart Failure, Aim 1
NCT05323487
Recruiting
This study will employ a randomized order, double-blind, repeated measures dose ranging design. This design was chosen in order to generate multiple within-subject serial loop diuretic dose response exposures. The overall study schema will include 75 heart failure (HF) patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/10/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Heart Failure
Register for Updates
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
NCT04567420
Recruiting
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)
Gender:
ALL
Ages:
All
Trial Updated:
01/10/2025
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Breast Cancer
Register for Updates
Combined THC and CBD for OUD and Chronic Pain
NCT06544291
Recruiting
The primary objective of this phase 2 study is to investigate the therapeutic potential of orally administered combined delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in relieving both pain and cue-induced opioid craving in people with co-occurring opioid use disorder (OUD) and chronic pain who are undergoing methadone therapy.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/09/2025
Locations: Connecticut Mental Health Center, New Haven, Connecticut
Conditions: Chronic Pain, Opioid Use Disorder
Register for Updates
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
NCT06179069
Recruiting
An Open-label, Multicenter Study of ZL-1310 as a Single Agent and In Combination with Atezolizumab to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small Cell Lung Cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Zai Lab Site 2030, New Haven, Connecticut
Conditions: SCLC
Register for Updates